Kiniksa Pharmaceuticals International, plc Financials
Kiniksa Pharmaceuticals International, plc (KNSA) reported $677.6M in revenue for fiscal year 2025, up 60.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Kiniksa’s 2025 inflection came from operating leverage: very high gross margins finally outran a still-heavy research and selling base.
Between FY2024 and FY2025, revenue scale did the heavy lifting: sales rose by$254M while SG&A plus R&D increased only about$14M , showing fixed-cost absorption rather than a wholesale cost reset. That is why operating income reached$77.2M and operating cash flow climbed to$138.0M , meaning the profit turn also arrived with cash.
The business has looked economically attractive for several years at the gross-profit line, with gross margin staying in the high-
Despite higher liabilities, the balance sheet still looks self-funded: cash of
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Kiniksa Pharmaceuticals International, plc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Kiniksa Pharmaceuticals International, plc has an operating margin of 11.4%, meaning the company retains $11 of operating profit per $100 of revenue. This results in a moderate score of 33/100, indicating healthy but not exceptional operating efficiency. This is up from -10.8% the prior year.
Kiniksa Pharmaceuticals International, plc's revenue surged 60.1% year-over-year to $677.6M, reflecting rapid business expansion. This strong growth earns a score of 95/100.
Kiniksa Pharmaceuticals International, plc carries a low D/E ratio of 0.35, meaning only $0.35 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 66/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 3.79, Kiniksa Pharmaceuticals International, plc holds $3.79 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 84/100.
Kiniksa Pharmaceuticals International, plc converts 20.1% of revenue into free cash flow ($136.4M). This strong cash generation earns a score of 75/100.
Kiniksa Pharmaceuticals International, plc's ROE of 10.4% shows moderate profitability relative to equity, earning a score of 35/100. This is up from -9.8% the prior year.
Kiniksa Pharmaceuticals International, plc scores 20.28, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($6.3B) relative to total liabilities ($196.0M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Kiniksa Pharmaceuticals International, plc passes 7 of 7 computable financial strength tests (2 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), all 1 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Kiniksa Pharmaceuticals International, plc generates $2.34 in operating cash flow ($138.0M OCF vs $59.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
Kiniksa Pharmaceuticals International, plc generated $677.6M in revenue in fiscal year 2025. This represents an increase of 60.1% from the prior year.
Kiniksa Pharmaceuticals International, plc's EBITDA was $78.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 279.4% from the prior year.
Kiniksa Pharmaceuticals International, plc reported $59.0M in net income in fiscal year 2025. This represents an increase of 236.6% from the prior year.
Kiniksa Pharmaceuticals International, plc earned $0.75 per diluted share (EPS) in fiscal year 2025. This represents an increase of 225.0% from the prior year.
Cash & Balance Sheet
Kiniksa Pharmaceuticals International, plc generated $136.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 436.8% from the prior year.
Kiniksa Pharmaceuticals International, plc held $165.6M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Kiniksa Pharmaceuticals International, plc's gross margin was 88.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 2.9 percentage points from the prior year.
Kiniksa Pharmaceuticals International, plc's operating margin was 11.4% in fiscal year 2025, reflecting core business profitability. This is up 22.2 percentage points from the prior year.
Kiniksa Pharmaceuticals International, plc's net profit margin was 8.7% in fiscal year 2025, showing the share of revenue converted to profit. This is up 18.9 percentage points from the prior year.
Kiniksa Pharmaceuticals International, plc's ROE was 10.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 20.3 percentage points from the prior year.
Capital Allocation
Kiniksa Pharmaceuticals International, plc invested $96.9M in research and development in fiscal year 2025. This represents a decrease of 13.2% from the prior year.
Kiniksa Pharmaceuticals International, plc invested $1.6M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 466.1% from the prior year.
Not reported for fiscal year 2025.
KNSA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $754.0M | $677.6M+60.1% | $423.2M+56.6% | $270.3M+22.7% | $220.2M+471.2% | $38.5M | N/A | N/A | N/A | N/A |
| Cost of Revenue | $80.6M | $77.7M+27.5% | $60.9M+82.3% | $33.4M+45.9% | $22.9M+151.6% | $9.1M | N/A | N/A | N/A | N/A |
| Gross Profit | $673.4M | $599.9M+65.6% | $362.3M+53.0% | $236.9M+20.1% | $197.3M+570.0% | $29.4M | N/A | N/A | N/A | N/A |
| R&D Expenses | $105.0M | $96.9M-13.2% | $111.6M+46.7% | $76.1M+16.2% | $65.5M-34.0% | $99.3M-11.4% | $112.0M-17.0% | $135.0M+55.9% | $86.6M+53.7% | $56.4M |
| SG&A Expenses | $213.9M | $196.3M+16.8% | $168.0M+29.8% | $129.4M+32.1% | $98.0M+14.0% | $85.9M+89.6% | $45.3M+29.6% | $35.0M+62.1% | $21.6M+138.4% | $9.0M |
| Operating Income | $93.2M | $77.2M+269.3% | -$45.6M-81.0% | -$25.2M-357.8% | $9.8M+106.2% | -$156.6M+0.5% | -$157.4M+7.4% | -$170.0M-57.1% | -$108.2M-65.4% | -$65.4M |
| Income Tax | $32.9M | $29.9M+324.1% | $7.0M+122.9% | -$30.7M+82.2% | -$172.3M-12543.1% | $1.4M-73.1% | $5.2M+351.7% | -$2.0M-856.5% | -$214K-10800.0% | $2K |
| Net Income | $73.1M | $59.0M+236.6% | -$43.2M-406.7% | $14.1M-92.3% | $183.4M+216.1% | -$157.9M+2.1% | -$161.4M+0.3% | -$161.9M-56.8% | -$103.2M-59.1% | -$64.9M |
| EPS (Diluted) | — | $0.75+225.0% | -$0.60-400.0% | $0.20-92.3% | $2.60+213.0% | -$2.30+11.9% | -$2.61+12.7% | -$2.99 | N/A | N/A |
Not reported in any period shown, so not listed: Interest Expense.
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
KNSA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $763.6M+31.5% | $580.6M+10.3% | $526.3M+14.5% | $459.7M+97.5% | $232.8M-33.4% | $349.5M+37.3% | $254.5M-20.9% | $322.0M+577.9% | $47.5M |
| Current Assets | $527.2M+58.9% | $331.8M+20.1% | $276.3M+13.7% | $243.1M+23.7% | $196.4M-41.1% | $333.2M+37.9% | $241.6M-23.0% | $313.8M+566.1% | $47.1M |
| Cash & Equivalents | $165.6M-9.8% | $183.6M+70.1% | $108.0M-12.0% | $122.7M+0.2% | $122.5M+7.4% | $114.0M+143.0% | $46.9M-34.8% | $72.0M+58.0% | $45.6M |
| Inventory | $54.9M+108.2% | $26.4M-15.3% | $31.1M+44.1% | $21.6M+487.7% | $3.7M | $0 | N/A | N/A | N/A |
| Accounts Receivable | $15.6M-62.6% | $41.7M+96.2% | $21.3M+68.0% | $12.7M+217.7% | $4.0M | N/A | N/A | N/A | N/A |
| Total Liabilities | $196.0M+37.9% | $142.1M+62.5% | $87.5M+37.7% | $63.5M+33.0% | $47.8M+27.3% | $37.5M+28.9% | $29.1M-31.8% | $42.7M-68.9% | $137.2M |
| Current Liabilities | $139.2M+38.3% | $100.6M+58.0% | $63.7M+35.3% | $47.1M+5.0% | $44.8M+40.8% | $31.8M+14.4% | $27.8M-34.6% | $42.6M+144.1% | $17.4M |
| Total Equity | $567.6M+29.5% | $438.4M-0.1% | $438.8M+10.8% | $396.1M+114.1% | $185.0M-40.7% | $311.9M+38.4% | $225.4M-19.3% | $279.3M+411.3% | -$89.7M |
| Retained Earnings | -$462.1M+11.3% | -$521.1M-9.0% | -$477.9M+2.9% | -$492.0M+27.1% | -$675.4M-30.5% | -$517.5M-45.3% | -$356.1M-83.3% | -$194.2M-113.4% | -$91.0M |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
KNSA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $165.9M | $138.0M+437.1% | $25.7M+93.1% | $13.3M+129.1% | $5.8M+104.6% | -$126.3M+7.5% | -$136.5M+13.8% | -$158.4M-95.5% | -$81.0M-61.3% | -$50.2M |
| Capital Expenditures | $1.6M | $1.6M+466.1% | $277K+113.1% | $130K+23.8% | $105K-74.7% | $415K+46.6% | $283K-91.2% | $3.2M-39.5% | $5.3M+7566.7% | $69K |
| Free Cash Flow | $164.2M | $136.4M+436.8% | $25.4M+92.9% | $13.2M+131.0% | $5.7M+104.5% | -$126.7M+7.4% | -$136.8M+15.3% | -$161.6M-87.2% | -$86.3M-71.6% | -$50.3M |
| Investing Cash Flow | -$169.4M | -$189.0M-601.7% | $37.7M+227.5% | -$29.6M-265.9% | -$8.1M-106.3% | $128.6M+648.7% | -$23.4M-147.6% | $49.2M+120.6% | -$239.2M-346563.8% | -$69K |
| Financing Cash Flow | $36.3M | $33.0M+169.2% | $12.3M+720.5% | $1.5M-40.6% | $2.5M-57.2% | $5.9M-97.4% | $227.1M+170.0% | $84.1M-75.7% | $346.7M+769.6% | $39.9M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0 |
Not reported in any period shown, so not listed: Share Buybacks.
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
KNSA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.5%+2.9pp | 85.6%-2.0pp | 87.6%-2.0pp | 89.6%+13.2pp | 76.4% | N/A | N/A | N/A | N/A |
| Operating Margin | 11.4%+22.2pp | -10.8%-1.5pp | -9.3%-13.8pp | 4.4% | -406.4% | N/A | N/A | N/A | N/A |
| Net Margin | 8.7%+18.9pp | -10.2%-15.4pp | 5.2%-78.1pp | 83.3% | -409.7% | N/A | N/A | N/A | N/A |
| Return on Equity | 10.4%+20.3pp | -9.8%-13.1pp | 3.2%-43.1pp | 46.3%+131.6pp | -85.4%-33.6pp | -51.7%+20.1pp | -71.8%-34.8pp | -37.0% | N/A |
| Return on Assets | 7.7%+15.2pp | -7.4%-10.1pp | 2.7%-37.2pp | 39.9%+107.7pp | -67.8%-21.7pp | -46.2%+17.4pp | -63.6%-31.5pp | -32.1%+104.5pp | -136.6% |
| Current Ratio | 3.79+0.5x | 3.30-1.0x | 4.34-0.8x | 5.16+0.8x | 4.38-6.1x | 10.46+1.8x | 8.68+1.3x | 7.37+4.7x | 2.70 |
| Debt-to-Equity | 0.350.0x | 0.32+0.1x | 0.200.0x | 0.16-0.1x | 0.26+0.1x | 0.120.0x | 0.130.0x | 0.15 | N/A |
| FCF Margin | 20.1%+14.1pp | 6.0%+1.1pp | 4.9%+2.3pp | 2.6% | -328.8% | N/A | N/A | N/A | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Kiniksa Pharmaceuticals International, plc Ranks
Frequently Asked Questions
What is Kiniksa Pharmaceuticals International, plc's annual revenue?
Kiniksa Pharmaceuticals International, plc (KNSA) reported $677.6M in total revenue for fiscal year 2025. This represents a 60.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Kiniksa Pharmaceuticals International, plc's revenue growing?
Kiniksa Pharmaceuticals International, plc (KNSA) revenue grew by 60.1% year-over-year, from $423.2M to $677.6M in fiscal year 2025.
Is Kiniksa Pharmaceuticals International, plc profitable?
Yes, Kiniksa Pharmaceuticals International, plc (KNSA) reported a net income of $59.0M in fiscal year 2025, with a net profit margin of 8.7%.
What is Kiniksa Pharmaceuticals International, plc's EBITDA?
Kiniksa Pharmaceuticals International, plc (KNSA) had EBITDA of $78.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Kiniksa Pharmaceuticals International, plc's gross margin?
Kiniksa Pharmaceuticals International, plc (KNSA) had a gross margin of 88.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Kiniksa Pharmaceuticals International, plc's operating margin?
Kiniksa Pharmaceuticals International, plc (KNSA) had an operating margin of 11.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Kiniksa Pharmaceuticals International, plc's net profit margin?
Kiniksa Pharmaceuticals International, plc (KNSA) had a net profit margin of 8.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Kiniksa Pharmaceuticals International, plc's return on equity (ROE)?
Kiniksa Pharmaceuticals International, plc (KNSA) has a return on equity of 10.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Kiniksa Pharmaceuticals International, plc's free cash flow?
Kiniksa Pharmaceuticals International, plc (KNSA) generated $136.4M in free cash flow during fiscal year 2025. This represents a 436.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Kiniksa Pharmaceuticals International, plc's operating cash flow?
Kiniksa Pharmaceuticals International, plc (KNSA) generated $138.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Kiniksa Pharmaceuticals International, plc's total assets?
Kiniksa Pharmaceuticals International, plc (KNSA) had $763.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Kiniksa Pharmaceuticals International, plc's capital expenditures?
Kiniksa Pharmaceuticals International, plc (KNSA) invested $1.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Kiniksa Pharmaceuticals International, plc spend on research and development?
Kiniksa Pharmaceuticals International, plc (KNSA) invested $96.9M in research and development during fiscal year 2025.
What is Kiniksa Pharmaceuticals International, plc's current ratio?
Kiniksa Pharmaceuticals International, plc (KNSA) had a current ratio of 3.79 as of fiscal year 2025, which is generally considered healthy.
What is Kiniksa Pharmaceuticals International, plc's debt-to-equity ratio?
Kiniksa Pharmaceuticals International, plc (KNSA) had a debt-to-equity ratio of 0.35 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Kiniksa Pharmaceuticals International, plc's return on assets (ROA)?
Kiniksa Pharmaceuticals International, plc (KNSA) had a return on assets of 7.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Kiniksa Pharmaceuticals International, plc's Altman Z-Score?
Kiniksa Pharmaceuticals International, plc (KNSA) has an Altman Z-Score of 20.28, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Kiniksa Pharmaceuticals International, plc's Piotroski F-Score?
Kiniksa Pharmaceuticals International, plc (KNSA) has a Piotroski F-Score of 7 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Kiniksa Pharmaceuticals International, plc's earnings high quality?
Kiniksa Pharmaceuticals International, plc (KNSA) has an earnings quality ratio of 2.34x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Kiniksa Pharmaceuticals International, plc?
Kiniksa Pharmaceuticals International, plc (KNSA) scores 65 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.